Spray dried inhalable ivacaftor co-amorphous microparticle formulations with leucine achieved enhanced in vitro dissolution and superior aerosol performance

Int J Pharm. 2022 Jun 25:622:121859. doi: 10.1016/j.ijpharm.2022.121859. Epub 2022 May 26.

Abstract

The present study aimed to develop inhalable powder formulations with both dissolution enhancement and superior aerodynamic properties for potential pulmonary delivery of a poorly water-soluble drug, ivacaftor (IVA). The IVA-leucine (LEU) microparticle formulations were produced by spray drying and the physicochemical, aerosolization and cytotoxicity properties were characterized. Co-amorphous microparticle formulation was formed at the IVA: LEU 3:1 M ratio with hydrogen bond interactions as indicated by Fourier transform infrared spectroscopy (FTIR) results. Dissolution rate of the co-spray dried formulations was significantly improved as compared with the IVA alone or physical mixtures. The co-spray dried formulations exhibited > 80% fine particle fraction (FPF) and > 95% emitted dose percentage (ED) values respectively, with superior physical and aerosolization stability under 40℃ at 75% RH for 30 days. The laser scanning confocal microscopy results demonstrated that more IVA was uptake by Calu-3 cell lines for the co-spray dried formulation. In summary, our results demonstrated that co-spray drying IVA with LEU could achieve enhanced in vitro release and superior aerodynamic properties for pulmonary delivery of IVA.

Keywords: Co-amorphous; Dissolution; Dry powder inhalation; Ivacaftor; Leucine.

MeSH terms

  • Administration, Inhalation
  • Aerosols / chemistry
  • Aminophenols
  • Dry Powder Inhalers*
  • Leucine / chemistry
  • Particle Size
  • Powders
  • Quinolones
  • Solubility

Substances

  • Aerosols
  • Aminophenols
  • Powders
  • Quinolones
  • ivacaftor
  • Leucine